Lorlatinib/lorlatinib latest price

Lorlatinib (Lorlatinib) is an oral, small-molecule ATP-competitive receptor tyrosine kinase, anaplastic lymphoma kinase (ALK), and C-rosc oncogene 1 (ROS 1) inhibitor designed to enter the central nervous system and overcome known secondary resistance mutations in the ALK tyrosine kinase domain. Based on the results of the CROWN phase trial, the third-generation macrocyclic ALK inhibitor lorlatinib has been introduced as a rescue option after failure of first-line TKI in ALK-rearranged non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) approved lorlatinib in 2021 for first-line treatment. In early 2022, it was approved as the first line in the United States, Europe, Japan and China.

The original drug Lorlatinib has been officially launched in the domestic market and has been included in the medical insurance system, reducing the financial burden on patients. Its common packaging specifications include 90 tablets of 25mg and 30 tablets of 100mg. However, due to the cost of new drug launches and research and development, its price is relatively high, with each box selling for about 10,000 to 20,000 yuan. If you purchase the Hong Kong original version, the price per box may fluctuate between RMB 30,000 and RMB 50,000 due to factors such as exchange rates.

However, there are more affordable generic drugs available in overseas markets, and the ingredients of these generic drugs are highly similar to the original drugs. For example, lorlatinib produced by a pharmaceutical factory in Laos has a specification of 100mg*30 tablets, and the price per box is only about 3,000 yuan. Although the price will also fluctuate due to the exchange rate, compared with the original drug, its cost-effective advantage is obvious. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.